We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson’s subsidiary Janssen has announced data from new analyses of its phase 3 clinical trial showing the benefit of the Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with peripheral arterial disease (PAD) after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Read More
Cerevance’s new phase 2 data suggests that its investigational Parkinson’s drug improves function without directly stimulating dopaminergic pathways. Read More
German device manufacturer Fresenius Kabi is acquiring a majority stake in mAbxience, the biosimilars division of Madrid, Spain-based Insud Pharma, for $547 million. Read More
The FDA has placed a partial clinical hold on CytoDyn’s human immunodeficiency virus (HIV) program and a full clinical hold on its COVID-19 program in the U.S. Read More
The FDA included detailed recommendations for booster shot studies in a final guidance on Emergency Use Authorizations (EUAs) for COVID-19 vaccines released yesterday. Read More
Akebia Therapeutics will have to conduct a new clinical trial if it wants to move its kidney disease drug vadadustat forward, the FDA said in a Complete Response Letter (CRL) denying approval for the investigational drug. Read More
Clovis Oncology’s Rubraca (Rucaparib) nearly halved the risk of disease progression in women with newly diagnosed advanced ovarian cancer following treatment combined with platinum-based chemotherapy. Read More